Frequency of treatment-related adverse events. (A) Most common treatment-related hematologic adverse events. (B) Most common treatment-related non-hematologic adverse events. Adverse events attributed by investigator to have “possible,” “probable,” or “definite” relation with the study drug were included. One patient experienced a grade 5 pneumonia event attributed to a possible relation to the study drug. ALP, alkaline phosphatase.